Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. H...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/10/12/e006082.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846159121778212864 |
|---|---|
| author | Manuela Eicher Massimo Di Maio George Coukos Lionel Trueb Matteo Morotti Eleonora Ghisoni Sara Colomer-Lahiguera |
| author_facet | Manuela Eicher Massimo Di Maio George Coukos Lionel Trueb Matteo Morotti Eleonora Ghisoni Sara Colomer-Lahiguera |
| author_sort | Manuela Eicher |
| collection | DOAJ |
| description | Adoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials. |
| format | Article |
| id | doaj-art-9e517d74a1674ea6840acf0cdd210cbf |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-9e517d74a1674ea6840acf0cdd210cbf2024-11-24T02:40:09ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262022-12-01101210.1136/jitc-2022-006082Patient-reported outcomes in adoptive cell-therapy trials: mind the gapManuela Eicher0Massimo Di Maio1George Coukos2Lionel Trueb3Matteo Morotti4Eleonora Ghisoni5Sara Colomer-Lahiguera6Institute of Higher Education and Research in Healthcare (IUFRS), Faculty of Biology and Medicine, University of Lausanne, Lausanne, SwitzerlandDepartment of Oncology, University of Turin, AOU Città della Salute e della Scienza di Torino, Torino, Italy3 Department of Oncology, Lausanne University Hospital, Lausanne, SwitzerlandDepartment of Oncology, Immuno-Oncology Service, University Hospital of Lausanne, CHUV, Lausanne, Vaud, SwitzerlandDepartment of Oncology, Immuno-Oncology Service, University Hospital of Lausanne, CHUV, Lausanne, Vaud, SwitzerlandDepartment of Oncology, Ludwig Institute for Cancer Research, Lausanne, SwitzerlandDepartment of Oncology, Lausanne University Hospital, Lausanne, SwitzerlandAdoptive cell therapies (ACT) have demonstrated promise in the treatment of patients with cancer, leading to long-lasting responses and, in some cases, even cure. Technological advances have brought these individualized therapies closer to reality, establishing them as credible therapeutic option. However, to date, few efforts have been made to understand patients' experience during ACT trials. Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs), which are instruments used to report PROs, are increasingly being used in oncology to capture patients’ perspective, provide real-world data on treatment safety, and support decision-making processes, such as health economic decisions. Due to the inherent complexity of ACT, the inclusion of PROMs in this field remains limited. In this commentary, we discuss the benefit of capturing PROs in ACT trials, the challenges of PROM administration and collection, and we propose simple and actionable recommendations to promote their adoption in ACT trials.https://jitc.bmj.com/content/10/12/e006082.full |
| spellingShingle | Manuela Eicher Massimo Di Maio George Coukos Lionel Trueb Matteo Morotti Eleonora Ghisoni Sara Colomer-Lahiguera Patient-reported outcomes in adoptive cell-therapy trials: mind the gap Journal for ImmunoTherapy of Cancer |
| title | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
| title_full | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
| title_fullStr | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
| title_full_unstemmed | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
| title_short | Patient-reported outcomes in adoptive cell-therapy trials: mind the gap |
| title_sort | patient reported outcomes in adoptive cell therapy trials mind the gap |
| url | https://jitc.bmj.com/content/10/12/e006082.full |
| work_keys_str_mv | AT manuelaeicher patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT massimodimaio patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT georgecoukos patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT lioneltrueb patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT matteomorotti patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT eleonoraghisoni patientreportedoutcomesinadoptivecelltherapytrialsmindthegap AT saracolomerlahiguera patientreportedoutcomesinadoptivecelltherapytrialsmindthegap |